Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

Yuichi Ando,¹ Megumi Inada-Inoue,¹ Ayako Mitsuma,¹ Takayuki Yoshino,² Atsushi Ohtsu,² Naoko Suenaga,³ Masahiko Sato,³ Tomoyuki Kakizume,³ Matthew Robson,⁷ Cornelia Quadt⁶ and Toshihiko Doi²

¹Nagoya University Hospital, Nagoya; ²National Cancer Center Hospital East, Kashiwa; ³Novartis Pharma K.K., Tokyo, Japan; ⁴Novartis Pharmaceuticals, East Hanover, New Jersey, USA

Buparlisib (BKM120) is an oral pan-phosphatidylinositol 3-kinase inhibitor, targeting all four isoforms of class I PI3K (α, β, γ and δ). This open-label Phase I dose-escalation study was conducted to determine the maximum tolerated dose of continuous daily buparlisib in Japanese patients with advanced solid tumors. Secondary objectives included safety and tolerability, pharmacokinetics, antitumor activity and pharmacodynamic marker changes. Fifteen patients were treated at 25 mg/day (n = 3), 50 mg/day (n = 3) and 100 mg/day (n = 9) dose levels. One dose-limiting toxicity of Grade 4 abnormal liver function occurred at 100 mg/day. Considering the safety profile and the maximum tolerated dose in the first-in-man study of buparlisib in non-Japanese patients, further dose escalation was stopped and 100 mg/day was declared the recommended dose. The most common treatment-related adverse events were rash, abnormal hepatic function (including increased transaminase levels), increased blood insulin levels and increased eosinophil count. Hyperglycemia was experienced by two patients, one Grade 1 and one Grade 4, and mood alterations were experienced by three patients, two Grade 1 and one Grade 2. Pharmacokinetic results showed that buparlisib was rapidly absorbed in a dose-proportional manner. Best overall response was stable disease for six patients, including one unconfirmed partial response. In these Japanese patients with advanced solid tumors, buparlisib had a manageable safety profile, with similar pharmacokinetics to non-Japanese patients. The recommended dose of 100 mg/day will be used in future studies of buparlisib in Japanese patients.

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is frequently activated in cancer,¹ and is implicated in the maintenance of a tumorigenic phenotype, tumor progression and resistance to anticancer therapy.²⁻⁵ Oncogenic pathway activation can occur through multiple mechanisms, including overexpression or activation of upstream receptor tyrosine kinases, or genetic alteration of individual pathway components. For example, activating mutations in the PIK3CA gene, which encodes the p110α isoform of the PI3K class IA catalytic subunit, are commonly found in cancer.² Given its pivotal role in cancer development and progression, pharmacologic inhibition of PI3K is currently being investigated as a potential therapeutic strategy for a range of tumors.

Buparlisib (BKM120 [Novartis Pharma AG, Basel, Switzerland]) is an oral pan-PI3K inhibitor that targets all four isoforms of class I PI3K (α, β, γ and δ).⁶ Buparlisib has demonstrated antiproliferative, pro-apoptotic and antitumor activity in cancer cell lines and tumor xenograft models, as a single agent⁶ and in combination with other anticancer therapies.⁷⁻⁹ In a first-in-man Phase I study in predominantly European and US patients with advanced solid tumors (NCT01068483), the maximum tolerated dose (MTD) of single-agent buparlisib given on a continuous daily schedule was 100 mg.¹⁰ Dose-limiting toxicities (DLT) occurred in seven of 30 evaluable patients, including epigastralgia, skin rash, mood alteration and hyperglycemia.¹⁰ In the safety expansion portion of the trial (n = 66), buparlisib was well tolerated with a minority of patients experiencing Grade 3/4 adverse events (AE).¹¹

The primary objective of this open-label Phase I dose-escalation study was to determine the MTD of oral buparlisib on a continuous daily schedule in adult Japanese patients with advanced solid tumors. Secondary objectives included assessments of safety and tolerability, characterization of the pharmacokinetic profile, evaluation of preliminary antitumor activity and changes in pharmacodynamic markers (as a measure of PI3K inhibition) of buparlisib.

Materials and Methods

Patient eligibility. Japanese patients ≥20 years of age with histologically confirmed, advanced, unrespectable solid tumors whose disease had progressed, or who were unable to tolerate standard therapy, or for whom no standard therapy existed were eligible. Other key inclusion criteria include: one
measurable or non-measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.0; an Eastern Cooperative Oncology Group performance status ≤2; life expectancy ≥12 weeks; adequate bone marrow, hepatic and renal functions; fasting plasma glucose levels ≤140 mg/dL (7.8 mmol/L); a negative pregnancy test ≤7 days of starting treatment for pre-menopausal and peri-menopausal women; and availability of a representative archival or fresh tissue specimen. Key exclusion criteria were: prior treatment with a PI3K inhibitor; clinically significant chronic liver disease; medically documented history of, or active, major mood or psychiatric disorder, or Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥3 anxiety; and clinically manifest diabetes mellitus or a history of gestational diabetes mellitus.

The study protocol was reviewed by regulatory authorities and approved by the ethics committees of all participating institutions. All patients provided written informed consent prior to any study assessments being performed. The study was conducted in accordance with the Declaration of Helsinki, guidelines for Good Clinical Practice as defined by the International Conference on Harmonization, and the Japanese Ministry of Health, Labour and Welfare.

**Study design and treatment.** In this Phase I open-label dose-escalation study (CBKM120X1101; NCT01283503), oral buparlisib was administered once daily, on a continuous schedule in 28-day cycles, starting at 25 mg/day. Patients received buparlisib until disease progression, unacceptable toxicity, investigator’s decision or patient’s withdrawal of consent.

An adaptive Bayesian logistic regression model (BLRM) with overdose control (EWOC) was used to guide dose escalation. The MTD was defined as the highest drug dosage not causing medically unacceptable DLT in more than 33% of treated patients during Cycle 1, which also satisfied the BLRM EWOC criteria. The population for MTD determination (the dose-determining set) consisted of patients treated for ≥21 days in Cycle 1, or who discontinued earlier due to a DLT. Patients who did not experience a DLT in Cycle 1 were observed for ≥28 days after the first dose, and completed all safety evaluations required for dose-determining decisions. To ensure the MTD recommendation was accurate, before a drug dosage could be declared, at least 15 patients eligible for the dose-determining set had to be enrolled, including at least six eligible patients receiving the estimated MTD. Intra-patient dose escalation was not permitted within the first four treatment cycles. The MTD was planned to be determined using the BLRM recommendation, plus a medical review of available clinical, pharmacokinetic and laboratory data.

**Definition of dose-limiting toxicity.** Dose-limiting toxicities were assessed using the National Cancer Institute’s CTCAE v3.0, and defined as AE or abnormal laboratory values that occurred within Cycle 1 and were suspected to be related to buparlisib. In addition, a DLT had to meet any of the criteria described in Table S1.

**Safety and antitumor activity assessments.** All patients who received at least one dose of the study drug and had at least one post-baseline safety assessment were eligible for safety evaluation. Routine clinical and laboratory assessments were conducted at baseline, and throughout the study. Other safety assessments included electrocardiogram and regular administration of a patient self-rating mood questionnaire (nine-item patient health questionnaire; PHQ-9).

Adverse events were collected continuously from the first dose to 4 weeks following the last dose of buparlisib, and graded using CTCAE v3.0 unless otherwise stated (Table S2). Mood alterations were defined as all AE belonging to one of the following MedDRA high-level group terms: mood disorders and disturbances, not elsewhere classified, and psychiatric and behavioral symptoms, not elsewhere classified.

Assessments of preliminary antitumor activity were performed in all patients who had received at least one dose of buparlisib. Radiologic response was measured by computed tomography (CT) or MRI according to RECIST v1.0 at baseline, at the end of Cycle 2 and every 8 weeks thereafter.

**Pharmacokinetic and pharmacodynamic assessments.** Blood was sampled for pharmacokinetic assessments after overnight fasting pre-dose, and 0.5, 1, 2, 4, 6, 8, 24 and 48 h post-dose on Days 1, 8 and 28 of Cycle 1, and pre-dose and 2–4 h post-dose on Day 1 of every other cycle from Cycle 3. Plasma samples were assayed using a validated liquid chromatography-tandem mass spectrometry assay (limit of quantitation was 0.25 ng/mL using 0.1 mL of plasma). Pharmacokinetic parameters, including the time of maximum buparlisib plasma concentration ($T_{\text{max}}$), maximum plasma concentration of buparlisib ($C_{\text{max}}$), area under the concentration–time curve over 24 h ($AUC_{0-24}$), buparlisib half-life ($T_{1/2}$) and the accumulation ratio (Race), were determined using a non-compartmental method.

Time-dependent changes in glucose metabolism markers (fasting plasma glucose, insulin and C-peptide levels) were collected pre-dose, and 0.5, 1, 2, 4 and 24 h post-dose at baseline (Cycle 1 Day 1), and then at Cycle 1 Days 8 and 28.

**Follow-up.** Patients whose treatment was interrupted or permanently discontinued due to a DLT, a study-related AE or an abnormal laboratory value were assessed at least once per week for 4 weeks and subsequently at 4-week intervals until resolution or stabilization of the event. Patients who required a dose delay ≥21 days from the last dose were discontinued from the study, and were followed for toxicities. Patients who discontinued study treatment were followed for AE and serious adverse events (SAE) for 28 days following the last dose of buparlisib.

**Results**

**Patient characteristics.** Fifteen patients were enrolled at two centers in Japan between October 2009 and October 2011 (Table 1). All 15 patients received at least one dose of buparlisib and so were evaluable for safety and preliminary efficacy.

**Dose escalation and maximum tolerated dose.** All 15 patients were evaluable for MTD determination. Of these, three patients were each allocated to the 25 and 50 mg/day dose cohorts, and nine patients to the 100 mg/day cohort. One DLT was reported in the study; this was Grade 4 abnormal liver function, which showed elevated liver function tests on Day 28 of Cycle 1, in a patient treated at 100 mg/day. Buparlisib was temporarily interrupted, but the patient did not resume study drug due to progressive disease and discontinued from the study. Recovery occurred approximately 1 month after onset. This DLT was the only incidence of Grade 3/4 abnormal liver function reported in Cycle 1, regardless of duration. The BLRM permitted a further dose increase to 150 mg/day, but considering safety information other than DLT, and the non-Japanese recommended Phase II dose, 100 mg/day was declared as the recommended dose (RD), instead of the MTD, for use in future buparlisib studies in Japanese patients.

**Safety and tolerability.** The median duration of exposure to buparlisib was 56 (range: 28–167) days in all patients and 37 (range: 28–129) days in patients receiving 100 mg/day.
patient had their dose reduced from 100 to 50 mg/day due to abnormal hepatic function, which occurred in Cycle 3. A total of 11 patients required dose interruptions due to AE.

All 15 patients experienced at least one AE suspected to be related to buparlisib (Table 2). Drug-related Grade 3/4 AE were abnormal hepatic function (including increased ALT/AST, n = 6) and anemia (n = 2). Mood alteration was experienced by 3 patients treated at 100 mg/day (all Grade 1 or 2); one patient was treated with tranquilizers; treatment was not required in the other two patients. No dose reductions or trial withdrawals resulting from mood alterations occurred.

Six patients treated at 100 mg/day experienced at least one SAE: abnormal hepatic function (Grade 3/4; including increased ALT/AST levels, n = 3), pneumonitis (Grade 3; n = 1), dyspea (Grade 2; n = 1) and hyperglycemia (Grade 4; n = 1), infectious pneumonia (Grade 2; n = 1), delirium (Grade 2; n = 1) and hemorrhage (Grade 4; n = 1). With the exceptions of delirium and hemorrhage, these SAEs were all considered related to buparlisib. Two patients, both in the 100 mg/day cohort, died during the study period (i.e. including the time on treatment and the safety follow-up period) as a result of SAEs (hemorrhage and pneumonitis). The patient with hemorrhage died 5 days after discontinuation of buparlisib due to a fistula in one of the cancer lesions resulting from tumor necrosis (Fig. 1): this was considered unrelated to buparlisib. A 71-year-old male patient died from aggravation of pneumonitis (Grade 5) 11 days after discontinuing buparlisib, for which a relationship to the study drug could not be ruled out. This patient was a non-smoker, with a diagnosis of adenocarcinoma of the rectum, multiple metastases, including the lung, pleura and lymph nodes, and a left pleural effusion, which was detected by a CT scan prior to study enrollment. A CT scan taken 32 days after the first dose of buparlisib administration showed pneumonitis and worsening disease with increased left pleural effusion. At the time of onset, infectious pneumonitis was suspected rather than interstitial pneumonia. Despite antibiotic treatment, the patient’s condition remained unchanged. When a follow-up CT examination was performed 10 days after the last dose of buparlisib, ground glass opacities were found. The patient’s respiratory function deteriorated abruptly, and the patient died the following day.

Five patients discontinued the study due to AE. In four patients, AE leading to discontinuation were considered related to the study drug. G, Grade.

### Table 1. Baseline patient characteristics

| Characteristic | 25 mg/day | 50 mg/day | 100 mg/day | All |
|---------------|-----------|-----------|------------|-----|
| n = 3 | n = 3 | n = 9 | n = 15 |
| Median age, years (range) | 66 (44-67) | 47 (22-66) | 58 (35-71) | 58 (22-71) |
| Sex, n | | | | |
| Male | 2 | 3 | 7 | 12 |
| Female | 1 | 0 | 2 | 3 |
| ECOG performance status, n | | | | |
| 0 | 3 | 2 | 5 | 10 |
| 1 | 0 | 1 | 4 | 5 |
| Prior antineoplastic regimens, n | | | | |
| Number of prior antineoplastic medication regimens, median (range) | 0 (0-3) | 5 (3-5) | 4 (0-9) | 3 (0-9) |
| Number of patients with >3 prior antineoplastic medication regimens | 0 | 1 | 5 | 6 |
| Primary site of tumor, n | | | | |
| Rectum | 0 | 0 | 3 | 3 |
| Salivary gland | 2 | 0 | 1 | 3 |
| Head and neck | 0 | 1 | 1 | 2 |
| Colon | 0 | 1 | 1 | 2 |
| Breast | 0 | 0 | 1 | 1 |
| Esophagus | 0 | 0 | 1 | 1 |
| Skin | 1 | 0 | 0 | 1 |
| melanoma | | | | |
| Peripheral nerve sheath | 0 | 1 | 0 | 1 |
| Unknown | 0 | 0 | 1 | 1 |

ECOG, Eastern Cooperative Oncology Group.

### Table 2. Study drug-related adverse events by treatment cohort and Grade

| Adverse events, n | 25 mg/day | 50 mg/day | 100 mg/day | All |
|------------------|-----------|-----------|------------|-----|
| n = 3 | n = 3 | n = 9 | n = 15 |
| Rash | 0 | 0 | 0 | 0 |
| Abnormal hepatic function/increased transaminase levels | 2 | 2 | 0 | 0 |
| Increased blood insulin levels | 0 | 0 | 1 | 0 |
| Increased eosinophil count | 3 | 0 | 0 | 0 |
| Increased blood C-peptide levels | 0 | 0 | 1 | 0 |
| Pruritus | 0 | 0 | 1 | 0 |
| Decreased appetite | 0 | 0 | 0 | 0 |
| Fatigue | 0 | 0 | 0 | 0 |
| Prolonged activated partial thromboplastin time | 0 | 0 | 1 | 0 |
| Anemia | 0 | 0 | 0 | 0 |
| Mood alteration | 0 | 0 | 0 | 0 |

†Adverse events (any Grade) reported in ≥3 patients; and all Grade 3/4 events considered related to the study drug, G, Grade.
target lesions for all patients is also shown in Fig. S1. The duration of stable disease ranged from 55 to 116 days. The disease control rate, defined as rates of complete response plus partial response plus stable disease, was 40%.

Pharmacokinetic and pharmacodynamics analyses. Pharmacokinetic data were obtained from all 15 patients, apart from at Cycle 1 Day 8 in two of the nine patients receiving buparlisib 100 mg/day (Table 4). Buparlisib was rapidly absorbed, achieving $C_{\text{max}}$ 1.0–1.5 h post-dose, as demonstrated by the $T_{\text{max}}$ values obtained on Days 1, 8 and 28 of Cycle 1 (Table 4; Fig. S2). At the MTD, buparlisib accumulated 2.8-fold on Cycle 1 Day 8 and 2.9-fold on Cycle 1 Day 28 compared with Cycle 1 Day 1, which was consistent with a half-life of approximately 40 h. Doses of buparlisib $\geq$50 mg/day led to steady-state exposure levels $\geq$10 000 ng*h/mL, which are estimated to be efficacious based on preclinical studies. $C_{\text{max}}$ and AUC$_{0-24}$ of buparlisib increased dose proportionately by 25–100 mg/day.

Modest time-dependent increases in glucose metabolism markers were observed with buparlisib treatment (see supporting information).

Discussion
This Phase I dose-escalation study evaluated the MTD of continuous once-daily buparlisib in Japanese patients with advanced solid tumors. Instead of the MTD, the RD of single-agent buparlisib was declared as 100 mg/day. Although the BLRM allowed higher doses to be evaluated, the decision to

| Clinical activity, $n$ (%) | 25 mg/day $n = 3$ | 50 mg/day $n = 3$ | 100 mg/day $n = 9$ | All $n = 15$ |
|---------------------------|-----------------|-----------------|-----------------|----------------|
| Complete response         | 0               | 0               | 0               | 0              |
| Partial response          | 0               | 0               | 0               | 0              |
| Stable disease            | 2 (66.7)        | 1 (33.3)        | 3 (33.3)+       | 6 (40.0)       |
| Disease progression       | 1 (33.3)        | 2 (66.7)        | 4 (44.4)        | 7 (46.7)       |
| Unknown                   | 0               | 0               | 2 (22.2)        | 2 (13.3)       |

†Includes one patient with unconfirmed partial response.
halt dose escalation and declare the RD was made on the basis of comparable pharmacokinetics with non-Japanese patients enrolled in the first-in-man study, and the safety profile of buparlisib in Japanese patients in this study. Therefore, the RD of once-daily buparlisib in Japanese patients with advanced solid tumors is the same as the MTD for buparlisib in the first-in-man study.

Buparlisib was generally well tolerated, with an AE profile reflective of on-target inhibition of the PI3K/Akt/mTOR pathway. The most common treatment-related AE were rash, abnormal hepatic function (including increased ALT/AST levels), increased blood insulin levels and increased eosinophil count, which are consistent with those AE reported in the first-in-man study, and for other pan-PI3K inhibitors. One DLT of abnormal liver function was reported in a patient in Cycle 1, and five further cases of Grade 3/4 abnormal hepatic function (including increased ALT/AST levels) were reported in Cycle 2 and thereafter. The hepatic toxicity was managed based on the Manual for Drug-Induced Liver Injury by the Ministry of Health, Labour and Welfare (Japanese Health Authority) guidelines and the Guidance for Industry, Drug-Induced Liver Injury of the FDA. Liver toxicity is considered to be a class effect of PI3K/Akt/mTOR pathway inhibitors. In clinical trials of PI3K inhibitors, liver enzyme abnormalities have been observed with varying frequencies. In a Phase I study investigating the PI3K inhibitor PX866, Grade 3 AST elevations were observed in two of 84 patients. In another Phase I study of the PI3K/mTOR inhibitor BGT226 in 57 patients with advanced solid tumors and lymphoma, AST elevations were the most frequently observed Grade 2 or higher biochemical abnormality. In the first-in-man study of buparlisib, Grade 3/4 liver toxicities (including transaminase increase and hyperbilirubinemia) were observed in nine patients (11%; mostly at 100 mg/day), and did not result in DLT. It is unknown whether differences in the occurrence of severe liver toxicity are significant between Japanese and non-Japanese patients because of the small sample size of this study, and potential differences in tumor types and treatment history. It is also unclear whether abnormal hepatic function is related to pharmacokinetic exposure to buparlisib. Incidences of abnormal hepatic function will be monitored in Phase II/III trials.

Hyperglycemia is another class effect of PI3K inhibitors due to the central role of PI3K/Akt/mTOR pathway in glucose homeostasis regulation. Inhibition of PI3K can lead to increased blood glucose levels by disrupting insulin signaling, inhibiting glycogen synthesis and reducing peripheral glucose uptake. Grade 4 hyperglycemia was observed in one patient receiving 100 mg/day in Cycle 2. In the first-in-man study, Grade 3/4 hyperglycemia occurred in three patients (9%), including two DLT at 150 mg/day. Clinical experience of buparlisib has shown that hyperglycemia can be managed with standard antidiabetes drugs, including metformin, and subcutaneous insulin where necessary. An in vivo study has suggested that fasting prior to drug administration and a low carbohydrate diet may reduce the extent of hyperglycemia caused by PI3K/Akt/mTOR pathway inhibition.

Glucose metabolism markers have been proposed as pharmacodynamic markers of PI3K inhibition. In this small study, there was a non-significant trend towards increased plasma glucose, C-peptide, and insulin levels with increasing concentrations of buparlisib. As no patient with diabetes participated in the study, the change in insulin levels reflected C-peptide levels as expected. Some patients in the 100 mg/day cohort showed increased glucose levels, but this was not thought to be associated with buparlisib exposure or clinical outcomes. In the first-in-man study, glucose metabolism markers indicated dose-dependent inhibition of PI3K signaling by buparlisib. Increases in C-peptide levels were observed at lower doses of buparlisib than those associated with hyperglycemia, indicating that increased pancreatic insulin/C-peptide release can effectively compensate for decreased glucose transport and metabolism due to PI3K inhibition at buparlisib doses less than 100 mg/day. Fasting blood glucose increases were also more evident at higher buparlisib doses, which is similar to the results observed here.

One patient in the 100 mg/day cohort died from drug-induced pneumonitis 11 days after discontinuing buparlisib due to progressive disease with a new lung lesion. As the patient’s respiratory function abruptly deteriorated just prior to his death, the investigator reasoned that the main cause of death was aggravation of pneumonitis rather than progression of cancer. This patient had lung pathology prior to entering the study, and was pretreated with multiple therapies previously associated with pneumonitis, possibly due to drug-induced lung injury. These include bevacizumab, oxaliplatin, levo-latanate, 5-FU, irinotecan and cetuximab. It has been speculated that inhibition of the PI3K/mTOR pathway may affect the immune system. However, unlike mTOR inhibitors that cause pneumonitis with varying frequencies, the PI3K inhibitor buparlisib has rarely been associated with pneumonitis in studies involving more than 500 patients (unpublished data). As a basic precaution for

### Table 4. Pharmacokinetic profile of oral buparlisib in adult Japanese patients with advanced solid tumors in Cycle 1

| Dose (mg/day) | Day | n | $T_{\text{max}}$ (h) | $C_{\text{max}}$ (ng/mL) | AUC$_{0-24}$ (ng*h/mL) | $T_{1/2}$ (h)† | Racc |
|--------------|-----|---|---------------------|-------------------------|-------------------------|----------------|------|
| 25           | 1   | 3 | 1.00                | 289 (45)                | 2060 (474)              | 36.8 (9.2)     | —    |
|              | 8   | 3 | 1.00                | 549 (275)               | 4640 (1230)             | 43.8 (NR)      | 2.25 (0.15) |
|              | 28  | 3 | 1.00                | 530 (131)               | 6800 (3040)             | NR             | 3.20 (0.67) |
| 50           | 1   | 3 | 1.02                | 595 (212)               | 3820 (834)              | NR             | 2.58 (1.16) |
|              | 8   | 3 | 1.10                | 738 (221)               | 9550 (3200)             | NR             | 3.09 (1.29) |
|              | 28  | 3 | 1.50                | 767 (121)               | 11400 (3320)            | NR             | 2.78 (0.66) |
| 100          | 1   | 9 | 1.50                | 1080 (331)              | 8800 (1530)             | 30.6 (9.6)     | —    |
|              | 8   | 7 | 1.02                | 1930 (503)              | 24300 (6190)            | 39.5 (25.2)    | —    |
|              | 28  | 9 | 2.98                | 1790 (503)              | 25000 (7950)            | 41.8 (16.9)    | 2.87 (0.83) |

| $AUC_{0-24}$ | Area under the curve from 0 to 24 h; $C_{\text{max}}$: maximum plasma concentration; NR, not reported; Racc, accumulation rate ($AUC_{[\text{Day } 0]} / AUC_{[\text{Day } 1]}$ or $AUC_{[\text{Day } 28]} / AUC_{[\text{Day } 1]}$); $T_{1/2}$: half-life; $T_{\text{max}}$: time at which maximum plasma concentration is achieved. Values are presented as median for $T_{\text{max}}$ and mean (standard deviation) for other parameters. †For $T_{1/2}$ analysis, for the 25-mg/day dose, n = 2 on Day 1 and n = 1 on Day 8; for the 100 mg/day dose n = 4 on Day 1, n = 3 on Day 8, and n = 2 on Day 28. |
patient safety, studies of buparlisib have required lung imaging as part of the study protocol at baseline and throughout the study if clinically indicated.

Mood alterations were observed in the first-in-man study of buparlisib: one DLT at 80 mg/day and two DLT at 100 mg/day.10) In Japanese patients, no Grade 3/4 mood alterations or DLT were observed. This difference between the two studies may be reflective of a protocol amendment excluding patients predisposed to mood alteration from the Japanese study, and the introduction of careful monitoring using PHQ-9. The incidence of all-grade mood alterations was similar between studies (3/15 [20%] in Japanese patients and 7/35 [20%] in non-Japanese patients).10) No dose reductions or trial withdrawals resulting from mood alterations occurred. In the first-in-man study, buparlisib-induced mood disorders were reversible, and resolved quickly upon treatment discontinuation.10) The occurrence of mood alterations with buparlisib has been attributed to its ability to cross the blood–brain barrier39) and to inhibit PI3K signaling in the brain parenchyma.40) The precise mechanism of buparlisib-induced mood disorders is still under investigation, but the PI3K/Akt/mTOR pathway is thought to play a role in neurotransmitter signaling.41–44) The ability of buparlisib to cross the blood–brain barrier may also have a beneficial effect on brain lesions.40)

Conclusions about the clinical activity of buparlisib cannot be made from the present study due to the small sample size and the heterogeneity of the patients enrolled. However, preliminary signs of clinical activity were observed, including stable disease and an unconfirmed partial response, indicating therapeutic potential in advanced solid tumors. Based on preclinical data, genetic alterations of the PI3K pathway, such as somatic PIK3CA mutations or PTEN loss, have been proposed to predict the response to PI3K pathway inhibitors, but early clinical results are inconclusive.45–50) Unfortunately, molecular profiling data were not available for the patient who experienced an unconfirmed partial response to buparlisib.

In conclusion, the results of this Phase I dose-escalation study demonstrate that the pan-class I inhibitor buparlisib has a manageable safety profile, has favorable pharmacokinetics, and has shown preliminary signs of antitumor activity in this small population of Japanese patients. Importantly, the safety and pharmacokinetic profiles of buparlisib were similar to those reported in the first-in-man trial in non-Japanese patients.10) The buparlisib dose of 100 mg/day has been determined as the RD for future studies of this schedule in Japanese patients. Phase III trials of buparlisib in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer are ongoing (BELLE-2 and BELLE-3).

Acknowledgments

We thank Dr Michio Imawari (Showa University School of Medicine) for consultation on hepatic toxicity, and Dr Masahiro Endo (Shizuoka Cancer Center), Dr Akifumi Kato (Kanagawa Cardiovascular and Respiratory Center) and Dr Masashi Takahashi (Shiga University of Medical Science) for external review of the interstitial lung disease case. We would also like to thank the patients who participated in this study and their families. Kate Gaffey PhD and Alison Lovibond PhD provided medical editorial assistance, funded by Novartis.

Disclosure statement

This study was supported by research funding from Novartis Pharma (CBKM120X1101). Yuichi Ando has received research funding from Novartis. Takayuki Yoshino has received honoraria from Takeda, Chugai and Merck Serono, and has received research funding from Yakult, Taiho, Daiichi-Sankyo and Lilly. Toshihiko Doi has received honoraria as lecture fees and research funding from Novartis. Naoko Suenaga, Masahiko Sato, Tomoyuki Kakezume, Matthew Robson and Cornelius Quadt are employees of Novartis Pharma, and Matthew Robson owns stocks in Novartis Pharma. The other authors have no conflict of interest to declare.

References

1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 56–66.
2. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase 3-pathway in cancer. Nat Rev Drug Discov 2009; 8: 627–44.
3. Saal LH, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564–9.
4. Huang WC, Hung MC. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009; 108: 180–94.
5. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and anti-estrogen resistance in breast cancer. J Clin Oncol 2011; 29: 4452–61.
6. Maira SM, Pecchi S, Huang A et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3K-inhibitor. Mol Cancer Ther 2012; 11: 317–28.
7. Ren H, Chen M, Yue P et al. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Lett 2012; 325: 139–46.
8. Mueller A, Bachmann E, Linnig M et al. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 2012; 69: 1601–15.
9. Park E, Park J, Han SW et al. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int J Oncol 2012; 40: 1259–66.
10. Bendell JC, Rodon J, Burris HA et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282–90.
11. Grana B, Burris H, Rodon J et al. Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: an update on safety and efficacy. J Clin Oncol 2011; 29 (suppl; abstr 3043).
12. Neuenschwander B, Brannon M, Gospodar W. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008; 27: 2420–39.
13. Babb J, Rogatko A, Zack S. Cancer phase I clinical trials: Efficient dose escalation with overdose control. Stat Med 1998; 17: 1103–20.
14. Von Hoff DD, LoRusso P, Tibes R et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2010; 28 (suppl; abstr 2541).
15. Munster PN, van der Noll R, Voest EE et al. Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumours (study F3K112826). J Clin Oncol 2011; 29 (suppl; abstr 3018).
16. Hong DS, Bowles DW, Falchouk GS et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 4173–82.
17. Japanese Health Authority, 2006. Manual for drug-induced liver injury by the Ministry of Health, Labour and Welfare (in Japanese). Available from URL: http://www.info.pmda.go.jp/jutouka/joutouka_index.html
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2009. Guidance for Industry. Drug-induced liver injury: premarketing clinical evaluation. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf.
19. Shimizu T, Tolcher AW, Papadopoulos KP et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012; 18: 2316–25.
Information on pharmacodynamic analyses.

Table S1. Best percentage change from baseline in target lesions according to dose of buparlisib and radiologic response.

Fig. S1. Additional supporting information may be found in the online version of this article:

Markman B, Tabernero J, Krop I et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 2012; 23: 2399–408.

Crouthamel MC, Kahana JA, Korenchuk S et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 2009; 15: 237–25.

Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85–96.

Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3K family defines a role for p110alpha in insulin signaling. Cell 2006; 125: 733–47.

Ready NE, Dudek AZ, Pang HH et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30336, a phase II study. J Clin Oncol 2011; 29: 4436–41.

Pontes LB, Armentano DP, Soares A, Gansl RC. Fatal pneumonitis induced by oxaliplatin: description of three cases. Case Rep Oncol 2012; 5: 104–9.

Fuse N, Ohtsu A, Ohtsu A et al. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. Jpn J Clin Oncol 2007; 37: 434–9.

Nakagawa M, Hamada A, Yoshihara Y et al. A case of interstitial lung diseases in patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4). Gan To Kagaku Ryoho 2011; 38: 317–20.

Hardy R, Cummings C, Faulkner M, Obianyo I. Pneumocystis carinii pneumonia following 5-fluorouracil administration. J Natl Med Assoc 1987; 79: 1205–9.

Fukuda M, Soda H, Fukuda M et al. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced non-small-cell lung cancer: a multi-institutional phase 2 study. Cancer 2007; 110: 606–13.

Takeda K, Negoro S, Kudoh S et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 1999; 79: 1462–7.

Chakravarthy AB, Tsai CJ, O’Brien N et al. A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Gastrointest Cancer Res 2012; 5: 112–18.

Blumenschein GR Jr, Paulus R, Curran WJ et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011; 29: 2312–18.

Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875–80.

Maroto JP, Hudes G, Dutcher JP et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011; 29: 1750–6.

Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010; 116: 4256–65.

White DA, Camus P, Endo M et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396–403.

Soria JC, Shepherd FA, Douillard JY et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20: 1674–81.

Iacovelli R, Palazzo A, Mezi S, Morano F, Nasso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012; 51: 873–9.

Nanni P, Nicoletti G, Palladini A et al. Multiorgan metastasis of human HER-2(+) breast cancer in Rag2(−/−);Il2rg(−/−) mice and treatment with PI3K inhibitor. PLoS ONE 2012; 7: e39626.

Maira M, Schnell C, Lollini P et al. Preclinical and preliminary clinical activity of NVP-BKM120, an an pan-class I PI3K inhibitor, in the brain. Ann Oncol 2012; 23 (suppl; abstr 1675).

Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Carson MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261–73.

Beaulieu JM, Sotnikova TD, Yao WD et al. Lithium antagonizes dopamine-dependent behaviors mediated by an Akt/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004; 101: 5099–104.

Chen L, Han L, Shi Z et al. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. Mol Med Rep 2012; 5: 575–9.

Bychkov E, Ahmed MR, Dalby KN, Gurevich EV. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 2007; 102: 699–711.

Janku F, Tsimeridou AM, Garrido-Laguna I et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors, Mol Cancer Ther 2011; 10: 558–65.

Janku F, Wheler JJ, Westin SN et al. PIK3/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777–82.

Juric D, Baselga J. Tumor genetic testing for patient selection in phase 1 clinical trials: The case of PI3K inhibitors. J Clin Oncol 2012; 30: 765–6.

Ille NT, Lemos R Jr, Wipf P et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009; 69: 143–50.

O’Brien C, Wallin JJ, Sampath D et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3’ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010; 16: 3670–83.

Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/AKT/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2012; 39: 313–20.